EnVivo Pharmaceuticals announced the initiation and dosing of patients in its Phase 2b study of EVP-6124 for the treatment of schizophrenia. This study is designed to randomize patients to two separate doses of EVP-6124 or placebo over three months at sites in the U.S. and Europe. The primary measures of efficacy will be computerized cognitive function. Secondary measures will include other cognitive and clinical measures. EnVivo expects the study to be fully enrolled in 2010 with data available in early 2011.
EVP-6124 is an investigational, selective agonist for the alpha-7 subtype of the nicotinic acetylcholine receptor. It is presently being developed for potential cognitive enhancement in both schizophrenia and Alzheimer’s patients.
For more information call (617) 225-4250 or visit www.envivopharma.com.